Needham & Company Downgrades Regulus Therapeutics (RGLS) to Hold

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. LITE
5. CL
6. LYB
7. TFII
8. NVT
9. SPY
10. AAPL

Go back to Needham & Company Downgrades Regulus Therapeutics (RGLS) to Hold

Regulus Announces Continuation of RG-101 Clinical Hold

January 27, 2017 4:10 PM EST

LA JOLLA, Calif., Jan. 27, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it received written communication from the U.S. Food and Drug Administration (FDA) that the clinical development program for RG-101 remains on clinical hold.  In June 2016, RG-101 was placed on clinical hold following the Company's submission of a second serious adverse event (SAE) of jaundice.

... More